NVAX
NASDAQ · Biotechnology
Novavax Inc
$9.53
-0.55 (-5.46%)
Financial Highlights (FY 2026)
Revenue
1.10B
Net Income
430.56M
Gross Margin
93.5%
Profit Margin
39.2%
Rev Growth
-17.2%
D/E Ratio
0.75
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 93.5% | 93.5% | 63.1% | 63.1% |
| Operating Margin | 37.7% | 34.0% | -1.5% | -1.6% |
| Profit Margin | 39.2% | 37.2% | -1.5% | -1.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.10B | 1.33B | 441.16M | 496.93M |
| Gross Profit | 1.03B | 1.24B | 278.28M | 313.45M |
| Operating Income | 414.73M | 451.01M | -6,707,375 | -7,754,591 |
| Net Income | 430.56M | 468.23M | -6,729,988 | -7,016,912 |
| Gross Margin | 93.5% | 93.5% | 63.1% | 63.1% |
| Operating Margin | 37.7% | 34.0% | -1.5% | -1.6% |
| Profit Margin | 39.2% | 37.2% | -1.5% | -1.4% |
| Rev Growth | -17.2% | -17.2% | +6.7% | +13.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 344.68M | 344.68M | 676.10M | 713.41M |
| Total Equity | 461.91M | 461.91M | 690.04M | 696.43M |
| D/E Ratio | 0.75 | 0.75 | 0.98 | 1.02 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 441.70M | 507.03M | -8,036,743 | -8,599,324 |
| Free Cash Flow | — | — | -9,195,591 | -10,064,458 |